BRIEF published on 03/22/2026 at 18:27, 1 hour 36 minutes ago Ad Hoc Announcement by EQS TEST MAILING CH Ad Hoc Announcement SIX Swiss Exchange Article 53 LR EQS TEST MAILING CH Procedural Focus
BRIEF published on 03/22/2026 at 18:27, 1 hour 36 minutes ago Annonce ponctuelle par EQS TEST MAILING CH SIX Swiss Exchange Annonce Ad Hoc Article 53 LR CHÈQUE DE TEST EQS Orientation Procédurale
PRESS RELEASE published on 03/22/2026 at 18:22, 1 hour 41 minutes ago Test news - please ignore EN EQS TEST MAILING CH announces release of ad hoc announcement pursuant to Art. 53 LR. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere. Lorem ipsum dolor sit amet Ad Hoc Announcement Art. 53 LR Announcement Lorem Ipsum EQS TEST MAILING CH
BRIEF published on 03/22/2026 at 12:28, 7 hours 35 minutes ago Borussia Dortmund Parts Ways with Sebastian Kehl Sports Leadership Borussia Dortmund Mutual Agreement Sebastian Kehl Future Changes
BRIEF published on 03/22/2026 at 12:28, 7 hours 35 minutes ago Le Borussia Dortmund se sépare de Sebastian Kehl Borussia Dortmund Leadership Sportif Sébastien Kehl Accord Mutuel Évolutions Futures
PRESS RELEASE published on 03/22/2026 at 12:23, 7 hours 40 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect Borussia Dortmund and Sebastian Kehl mutually agree to end collaboration immediately, marking a turning point in sporting leadership Collaboration Departure Borussia Dortmund Sebastian Kehl Sporting Leadership
BRIEF published on 03/21/2026 at 10:10, 1 day 9 hours ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 1 day 9 hours ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 1 day 9 hours ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
PRESS RELEASE published on 03/21/2026 at 10:05, 1 day 9 hours ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
Published on 03/20/2026 at 13:30, 2 days 6 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 7 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 7 hours 40 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 21 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
